Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/10/2026, 12:00:00 AM
FDA decision on oral weight-loss drug orforglipron is expected; high importance is estimated due to potential for >=10% price impact.
Korean Translation
경구용 비만 치료제 올포글리프론(orforglipron)에 대한 FDA 승인 결정이 예상되며, 10% 이상의 주가 영향 가능성에 따라 높은 중요도가 예상됨.
Related Recent Events
Micron Technology Inc. (MU) · Earnings Release
Micron's fiscal third-quarter 2026 earnings release is scheduled for June 24, 2026, scheduled. High importance is estimated as earnings releases for major semiconductor companies typically result in price impacts exceeding 10%.
6/24/2026, 12:00:00 AM
Apple Inc (AAPL) · Other
Apple's annual Worldwide Developers Conference (WWDC) is scheduled to begin on June 8, 2026, to unveil iOS 27 and major AI advancements; these updates are estimated to have a >5% price impact scheduled
6/8/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Hewlett Packard Enterprise Co is expected to announce its Q2 2026 earnings results on June 2, 2026 scheduled.
6/2/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
Q4 2026 earnings release including analyst EPS forecasts of $2.25-$2.27 forecasted, scheduled. Medium importance estimated as quarterly earnings are major catalysts for this stock.
5/28/2026, 12:00:00 AM
Palo Alto Networks Inc (PANW) · Earnings Release
Palo Alto Networks' next earnings release for Q3 2026 is scheduled for May 19, 2026. Low importance as it is a routine scheduled announcement with no results yet, scheduled.
5/19/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Next earnings release for Q1 2026 is scheduled for 2026-05-14, with analysts forecasting an EPS of -$0.04. A neutral impact is expected as the market typically waits for actual results, so the release is forecasted and scheduled.
5/14/2026, 12:00:00 AM